CN112352046A - 麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用 - Google Patents

麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用 Download PDF

Info

Publication number
CN112352046A
CN112352046A CN201980043514.6A CN201980043514A CN112352046A CN 112352046 A CN112352046 A CN 112352046A CN 201980043514 A CN201980043514 A CN 201980043514A CN 112352046 A CN112352046 A CN 112352046A
Authority
CN
China
Prior art keywords
medium
ascorbic acid
myogenic differentiation
egt
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980043514.6A
Other languages
English (en)
Chinese (zh)
Inventor
小坂邦男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagase and Co Ltd
Original Assignee
Nagase and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagase and Co Ltd filed Critical Nagase and Co Ltd
Publication of CN112352046A publication Critical patent/CN112352046A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pediatric Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980043514.6A 2018-06-29 2019-06-11 麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用 Pending CN112352046A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-124613 2018-06-29
JP2018124613 2018-06-29
PCT/JP2019/023114 WO2020004014A1 (ja) 2018-06-29 2019-06-11 エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用

Publications (1)

Publication Number Publication Date
CN112352046A true CN112352046A (zh) 2021-02-09

Family

ID=68986429

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980043514.6A Pending CN112352046A (zh) 2018-06-29 2019-06-11 麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用

Country Status (6)

Country Link
US (1) US12454678B2 (enExample)
EP (1) EP3816278A4 (enExample)
JP (3) JP7759724B2 (enExample)
CN (1) CN112352046A (enExample)
TW (1) TWI815907B (enExample)
WO (1) WO2020004014A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117396198A (zh) * 2021-05-20 2024-01-12 南京纽邦生物科技有限公司 改善和预防年龄相关性肌肉退化的方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022230487A1 (enExample) * 2021-04-26 2022-11-03
JP7569818B2 (ja) * 2022-03-11 2024-10-18 キッコーマン株式会社 エルゴチオネインを光に対し安定化させた液体組成物
JPWO2024172003A1 (enExample) * 2023-02-16 2024-08-22
DE102023131771B3 (de) 2023-09-15 2025-02-06 Esspen Gmbh Verfahren und Vorrichtung zur Verarbeitung medizintechnischer Bilddaten im Zusammenhang mit einer Trepanation
WO2026148341A1 (en) * 2025-01-06 2026-07-09 Mironova Labs, Inc ʟ-ERGOTHIONEINE COCRYSTAL AND DERIVATIVES

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099277A1 (en) 2002-05-20 2003-12-04 Oxis International, Inc. Method of reducing incidence diabetic embryopathy with l-ergothioneine
US20100227307A1 (en) 2007-04-12 2010-09-09 Hausman Marvin S Ergothioneine and/or its derivatives as a cell preservative
FR2924334B1 (fr) 2007-11-30 2016-03-25 Lvmh Rech Composition cosmetique comprenant l'acide 2-glucoside ascorbique et l'ergothioneine.
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US20120141611A1 (en) * 2010-12-05 2012-06-07 Oxis International Inc. Methods and compositions using ergothioneine to treat a variety of health related factors
CA2877861A1 (en) * 2012-06-26 2014-01-03 Entia Biosciences, Inc. A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2
TWI549696B (zh) 2014-09-05 2016-09-21 中國醫藥大學 麥角硫因應用於活化細胞之Ｎｒｆ２訊息途徑之用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117396198A (zh) * 2021-05-20 2024-01-12 南京纽邦生物科技有限公司 改善和预防年龄相关性肌肉退化的方法

Also Published As

Publication number Publication date
JP2025148417A (ja) 2025-10-07
EP3816278A4 (en) 2022-05-04
US20210130787A1 (en) 2021-05-06
US12454678B2 (en) 2025-10-28
TW202015549A (zh) 2020-05-01
TWI815907B (zh) 2023-09-21
JP7759724B2 (ja) 2025-10-24
WO2020004014A1 (ja) 2020-01-02
JPWO2020004014A1 (ja) 2021-07-15
EP3816278A1 (en) 2021-05-05
JP2024026241A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7759724B2 (ja) エルゴチオネイン、アスコルビン酸２－グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
US20170042924A1 (en) Muscle atrophy inhibitor containing quercetin glycoside
JP2020528085A (ja) 幹細胞から抽出されたエキソソームを有効成分として含む骨粗鬆症の予防または治療用の組成物
CN111616979A (zh) 一种包括核酸片段的混合物的组合物及其用途
US20190038769A1 (en) Micro-rna profiling, compositions, and methods of treating diseases
CN111032677A (zh) 用于抑制骨吸收的肽
TW201713330A (zh) 肌肉脂肪化抑制用組成物
US11096917B2 (en) Composition for preventing or treating muscle diseases, comprising suberic acid or pharmaceutically acceptable salt thereof as active ingredient
KR20200000146A (ko) 비트린의 억제제를 유효성분으로 포함하는 페이로니병의 예방 또는 치료용 조성물
JP2014015429A (ja) サテライト細胞分化促進剤
KR101348550B1 (ko) α-리포산 또는 이의 유도체에서 선택된 어느 하나 또는 둘 이상의 화합물을 유효성분으로 함유하는 갑상선암 치료용 약학조성물
JP2024100951A (ja) アトロジン－１発現抑制剤
WO2020170388A1 (ja) Ｉ型コラーゲン又はエラスチンの産生促進剤
TWI625124B (zh) 嗜熱鏈球菌tci633菌株及其代謝產物於預防及／或治療骨質疏鬆症之應用
KR102521988B1 (ko) 감마-글루타밀티로신을 포함하는 암 치료 또는 예방용 약제학적 조성물
JP2024070649A (ja) 筋萎縮抑制剤及び筋萎縮防止用組成物
JP5930507B2 (ja) ヒアルロン酸産生促進剤
US12576101B2 (en) Application based nucleotides of Lactobacillus rhamnosus to prepare a composition for anti-lipogenesis
JP2014015428A (ja) サテライト細胞分化促進剤
US12606824B2 (en) Micro-RNA profiling, compositions, and methods of treating diseases
JP2012136448A (ja) 神経細胞活性化剤
JP6168485B2 (ja) ヒアルロン酸産生促進剤
EP4245307A1 (en) Composition for preventing or treating muscle diseases, containing stem cells in which gro-? is expressed or gro-?
JP5923404B2 (ja) Ｔｒｐｖ４活性抑制剤
TW202525304A (zh) 包含核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination